Heart failure & cardiomyopathiesRandomised controlled trial
A Novel Controlled Metabolic Accelerator for the Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction: Rationale and Design of the Phase 2a HuMAIN Trial
- Rationale and design of a phase 2a randomised controlled trial
- double-blind
- placebo-controlled
- dose-titration
- parallel-group
Evaluates effects of HU6 on weight loss, body composition, exercise capacity, cardiac structure and function, metabolism and inflammation, and identifies optimal dosage for future Phase 3 trials
Authors' conclusion
HuMAIN will test a promising novel agent for obesity-related HFpEF.
Study context
- Population
- Patients with obesity-related heart failure with preserved ejection fraction (HFpEF)
- Comparison
- HU6 vs placebo
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
A Novel Controlled Metabolic Accelerator for the Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction: Rationale and Design of the Phase 2a HuMAIN Trial. Eur J Heart Fail. Published 26 June 2024. doi:10.1002/ejhf.3305
Summarised from the published abstract; every number is checked against it